Last reviewed · How we verify
Ethinylestradiol/levonorgestrel
Ethinylestradiol/levonorgestrel is a combined oral contraceptive that suppresses ovulation by inhibiting gonadotropin-releasing hormone (GnRH) and preventing the luteinizing hormone (LH) surge required for egg release.
Ethinylestradiol/levonorgestrel is a combined oral contraceptive that suppresses ovulation by inhibiting gonadotropin-releasing hormone (GnRH) and preventing the luteinizing hormone (LH) surge required for egg release. Used for Contraception / prevention of pregnancy, Regulation of menstrual cycles.
At a glance
| Generic name | Ethinylestradiol/levonorgestrel |
|---|---|
| Also known as | Microgynon 30, RVG 08204 |
| Sponsor | Leiden University Medical Center |
| Drug class | Combined oral contraceptive |
| Target | Estrogen receptor (ER), Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | Phase 3 |
Mechanism of action
Ethinylestradiol is a synthetic estrogen and levonorgestrel is a synthetic progestin. Together, they provide negative feedback to the hypothalamic-pituitary-ovarian axis, preventing follicle-stimulating hormone (FSH) and LH secretion. This dual hormonal action prevents ovulation, thickens cervical mucus to impede sperm transport, and alters the endometrium to reduce implantation likelihood.
Approved indications
- Contraception / prevention of pregnancy
- Regulation of menstrual cycles
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Venous thromboembolism
- Hypertension
Key clinical trials
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (PHASE1)
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
- Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR (PHASE2)
- A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives (PHASE1)
- A Study of Elenestinib in Healthy Adult Female Participants (PHASE1)
- A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethinylestradiol/levonorgestrel CI brief — competitive landscape report
- Ethinylestradiol/levonorgestrel updates RSS · CI watch RSS
- Leiden University Medical Center portfolio CI